Organization
Heidelberg University Hospital
4 abstracts
1 poster
Abstract
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.Org: University of Paris-Saclay, Peter MacCallum Cancer Centre, Melbourne, Australia, National Cancer Center Hospital East, Kashiwa, Japan, Vall d’Hebron University Hospital/VHIO, Barcelona, Spain,
Abstract
N2M2/NOA-20: Phase I/IIa umbrella trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation.Org: University of Heidelberg, NCT Heidelberg, Heidelberg University Hospital, Department of Neurology and Hematology-Oncology, Department of Neuroradiology,
Abstract
Cost-utility analysis of a supervised exercise program for patients with metastatic breast cancer in the PREFERABLE-EFFECT randomized controlled trial (RCT).Org: University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht University, German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT) Heidelberg,
Abstract
Efficacy and safety of erdafitinib in pediatric patients with advanced solid tumors and FGFR alterations in the phase 2 RAGNAR trial.Org: Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), Memorial Sloan Kettering Cancer Center, FLENI,